The pharmaceutical sector experienced diverse movements during the week of November 25–29, 2024. Among the notable performers, Biocon Ltd led the gains with a significant surge of ₹30.35 (9.08%), closing at ₹364.75. Torrent Pharmaceuticals Ltd followed with a rise of ₹155.70 (4.91%), ending the week at ₹3,330.00. Meanwhile, Mankind Pharma Ltd saw a decline of ₹31.90 (1.23%), closing at ₹2,560.10.
Top Gainers
- Biocon Ltd: +₹30.35 (+9.08%) to ₹364.75.
- Torrent Pharmaceuticals Ltd: +₹155.70 (+4.91%) to ₹3,330.00.
- Cipla Ltd: +₹37.95 (+2.54%) to ₹1,532.00.
- Divi’s Laboratories Ltd: +₹152.70 (+2.53%) to ₹6,183.25.
Weekly Performance Table
| Stock | Closing Price (₹) | Weekly Gain/Loss (₹) | Weekly Change (%) |
|---|---|---|---|
| Biocon Ltd | 364.75 | +30.35 | +9.08 |
| Torrent Pharmaceuticals Ltd | 3,330.00 | +155.70 | +4.91 |
| Cipla Ltd | 1,532.00 | +37.95 | +2.54 |
| Divi’s Laboratories Ltd | 6,183.25 | +152.70 | +2.53 |
| Glenmark Pharmaceuticals | 1,528.10 | +23.45 | +1.56 |
| Zydus Lifesciences | 965.20 | +14.95 | +1.57 |
| Aurobindo Pharma | 1,258.20 | +15.20 | +1.22 |
| Alkem Laboratories | 5,635.75 | +15.10 | +0.27 |
| Sun Pharmaceutical | 1,784.00 | -15.55 | -0.86 |
| Dr. Reddy’s Laboratories | 1,202.45 | -11.50 | -0.95 |
| Mankind Pharma Ltd | 2,560.10 | -31.90 | -1.23 |
| Lupin Ltd | 2,052.00 | -38.10 | -1.82 |
Sector Highlights
- Biocon Ltd emerged as the standout performer, benefiting from strong investor sentiment and sector-specific developments.
- Torrent Pharmaceuticals Ltd continued its upward momentum, reflecting robust investor confidence.
- On the downside, Mankind Pharma Ltd and Lupin Ltd faced declines amid subdued market activity in their counters.
The pharma sector displayed a mixed trend, with certain stocks outperforming and others facing headwinds. Investors may watch upcoming market developments and company-specific announcements for further insights.
Disclaimer:
This article is for informational purposes only and should not be interpreted as financial or investment advice. Readers are advised to consult with a professional financial advisor before making any investment decisions.
